within Pharmacolibrary.Drugs.ATC.B;

model B03AB10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.14,
    Cl             = 0.9 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 1800
  );

  annotation(Documentation(
    info ="<html><body><p>Ferric maltol is an oral iron replacement therapy indicated for the treatment of iron deficiency anemia in adults. It is approved for clinical use in several countries and is known for improved gastrointestinal tolerability compared to traditional oral iron salts.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration of ferric maltol 30 mg.</p><h4>References</h4><ol><li><p>Allen, S, et al., &amp; Vadamalayan, B (2021). Safety, Tolerability, and Pharmacokinetics of Oral Ferric Maltol in Children With Iron Deficiency: Phase 1 Study. <i>JPGN reports</i> 2(3) e090–None. DOI:<a href=&quot;https://doi.org/10.1097/PG9.0000000000000090&quot;>10.1097/PG9.0000000000000090</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37205968/&quot;>https://pubmed.ncbi.nlm.nih.gov/37205968</a></p></li><li><p>Khoury, A, et al., &amp; Farland, MZ (2021). Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults. <i>The Annals of pharmacotherapy</i> 55(2) 222–229. DOI:<a href=&quot;https://doi.org/10.1177/1060028020941014&quot;>10.1177/1060028020941014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32633548/&quot;>https://pubmed.ncbi.nlm.nih.gov/32633548</a></p></li><li><p>Bokemeyer, B, et al., &amp; Mallard, N (2017). Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency. <i>European journal of drug metabolism and pharmacokinetics</i> 42(2) 229–238. DOI:<a href=&quot;https://doi.org/10.1007/s13318-016-0334-5&quot;>10.1007/s13318-016-0334-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27101422/&quot;>https://pubmed.ncbi.nlm.nih.gov/27101422</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03AB10;
